

TUFTS CSDD EXECUTIVE FORUM

MEMBER REGISTRATION

YOU ARE INVITED TO JOIN

Contact information

Name _____ Degree _____

Title _____

Department or Specialization _____

Company/Organization _____

Mailing Address _____

City _____ State/Prov. _____ Zip Code _____

Country _____

Work Phone _____ Fax _____

Email _____

Please tell us how you heard about the Forum:

Email Brochure Mailer Website Colleague Other

Annual membership fee US\$6,825

Annual membership, if from a Tufts CSDD sponsoring organization US\$5,995

Amount enclosed/charged _____

Method of payment:

Check (Please make check payable to Trustees of Tufts College.)

MasterCard Visa American Express

Card Number _____

Exp. Date _____ Today's Date _____

Signature _____

(Required for processing)

Send completed registration form to:

Tufts Center for the Study of Drug Development
75 Kneeland Street, Suite 1100, Boston, MA 02111, USA

Or fax completed form to 617-636-2425

For more information:

Tel: 617-636-2170

Email: csdd@tufts.edu



Tufts Center for the
Study of Drug Development
TUFTS UNIVERSITY



TUFTS CSDD EXECUTIVE FORUM

A PROGRAM OF HIGHLY INTERACTIVE ONE-DAY
ROUNDTABLE DISCUSSIONS FOR SENIOR R&D
LEADERS, HOSTED BY THE TUFTS CENTER FOR
THE STUDY OF DRUG DEVELOPMENT



Tufts Center for the
Study of Drug Development

TUFTS UNIVERSITY

Roundtable I: Thursday, February 25

Improving ROI and Late Stage Clinical Success Rates

In an effort to boost ROI, many companies are looking to new operational strategies that leverage available data and improve Phase 1 and 2 design in an effort to maximize the likelihood of late stage clinical success. This roundtable will focus on different approaches taken by research-based large and small pharma and biotech firms to increase late stage success rates and boost ROI.

Roundtable II: Thursday, May 13

Strategies for Managing Drug Development Risk: Maintaining Portfolio Diversity

Across the pharma and biotech industry, companies are assessing strategies for managing risk in their development portfolios. Strategies range from new risk-sharing partnerships, to integrated network approaches to R&D, to an increased focus on targeted medicines development. This roundtable will examine company reviews of the obstacles and opportunities offered by these and other risk mitigating strategies.

Roundtable III: Thursday, September 16

Outsourcing Strategies Across the Value Chain

Many companies have begun to reassess what they consider their core competencies. The result has been the evolution of a networked approach to pharma R&D, in which strategic partners provide critical capabilities along the entire value chain. In this roundtable, a presentation of Tufts CSDD findings on strategic outsourcing trends across the industry will be followed by specific examples of outsourcing strategies in both large and small pharma and biotech companies.

Roundtable IV: Thursday, November 4

Strategies for Optimizing the Drug Development Process: Translational Science, New Technologies, and Clinical Design Improvements

The increasing size and complexity of clinical protocols is straining R&D budgets and extending development timelines. Translational science, however, has led to the introduction of new tools and technologies to improve the screening of candidate compounds and the design of clinical programs. This roundtable will focus on those tools and technologies that provide the greatest benefits and how companies have integrated them into their R&D activities.

“... an excellent opportunity to exchange ideas and discuss R&D trends with a focused group of senior leaders from a wide variety of firms within the bio-pharmaceutical industry. Common themes emerge despite the different size and focus of the companies represented.”

Paul Biondi, Vice President, R&D Operations, BMS

In response to industry requests, the Tufts CSDD Executive Forum was created in 2008 to provide its members with the opportunity to share ideas and hear colleagues discuss their experiences with R&D practices and strategies.

Hosted by Tufts CSDD at its offices at 75 Kneeland Street, Suite 1100, Boston, roundtables run from 10 a.m. to 4 p.m.

Typically at each roundtable, Tufts CSDD presents current information on the topic of the meeting, followed by industry speakers who present case studies on their companies' experiences. Open discussion by all attendees generates a lively exchange on the pros and cons of different approaches to solving specific R&D management problems, and identifies best practices.

Membership in the Tufts CSDD Executive Forum provides:

- Quarterly roundtables focused on topical R&D issues for up to two people per member organization.
- *Tufts CSDD R&D Management Reports* summarizing the main discussion points of each roundtable.
- Presentations on cutting-edge research.
- Opportunity to network with industry colleagues.

Cost of Membership

An annual membership to the Tufts CSDD Executive Forum is \$6,825. Sponsoring organizations of the Tufts Center for the Study of Drug Development receive a 10 percent discount and pay \$5,995.